On August 30, 2024 Innocure Therapeutics (CEO Yoo Hye-dong, Innocure), a company specializing in the development of targeted protein degradation (TPD) drugs, reported that Chief Strategy Officer (CSO) Kang Jong-seok will present the research results related to the company’s non-clinical candidate substance ‘ICT-1402’ decomposition agent at ‘BioCentury’s Grand Rounds R&D Conference 2024’ to be held in Nashville, Tennessee, USA from September 9th to 11th (local time) (Press release, InnoCure Therapeutics, AUG 30, 2024, View Source [SID1234651743]).
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
This inaugural event, hosted by BioCentury, is a global conference that presents groundbreaking research, clinical insights, and innovative technologies with commercial potential for the next generation of biotech innovation.
InnoCure announced at the conference that its non-clinical non-small cell lung cancer decomposition agent ICT-1402 showed a tumor growth factor receptor (TGI) of 110% compared to the vehicle group in a patient-derived xenograft (PDX) model experiment with epidermal growth factor receptor (EGFR) exon 19 deletion and mesenchymal-to-epithelial transition (MET) amplification mutation in the 6 mpk group, and was more effective than the control drug Tepotinib 6 mpk group with a TGI of 75%.
Yoo Hye-dong, CEO of Innocure, said, "Through this event, we will promote ICT-1402, a global leading MET decomposer, and achieve business results that will accelerate future technology transfer (L/O) efforts." Meanwhile, Innocure was selected as a baby unicorn company for the ‘Global Unicorn Development Project’ last June.